[go: up one dir, main page]

IS5183A - Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs - Google Patents

Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs

Info

Publication number
IS5183A
IS5183A IS5183A IS5183A IS5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A
Authority
IS
Iceland
Prior art keywords
drug
unfinished
assessing
unprocessed
neoplastic
Prior art date
Application number
IS5183A
Other languages
English (en)
Inventor
Niwa Kozo
Original Assignee
Niwa Kozo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niwa Kozo filed Critical Niwa Kozo
Publication of IS5183A publication Critical patent/IS5183A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/071—Agaricus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS5183A 1998-09-17 1999-09-17 Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs IS5183A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (ja) 1998-09-17 1998-11-13 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法

Publications (1)

Publication Number Publication Date
IS5183A true IS5183A (is) 2000-03-17

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5183A IS5183A (is) 1998-09-17 1999-09-17 Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs

Country Status (19)

Country Link
JP (1) JP2000159682A (is)
KR (1) KR20000023206A (is)
CN (1) CN1255376A (is)
AU (1) AU4486299A (is)
BE (1) BE1012725A5 (is)
CA (1) CA2282234A1 (is)
DE (1) DE19944695A1 (is)
DK (1) DK199901235A (is)
ES (1) ES2155802B1 (is)
FR (2) FR2783426A1 (is)
GB (2) GB9920710D0 (is)
ID (1) ID23150A (is)
IL (1) IL131722A0 (is)
IS (1) IS5183A (is)
IT (1) IT1307267B1 (is)
NL (2) NL1013049C2 (is)
NO (1) NO994463L (is)
SE (2) SE9903307L (is)
SG (1) SG76631A1 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633601B2 (ja) * 2001-04-27 2005-03-30 味の素株式会社 免疫賦活剤
WO2002090559A1 (en) * 2001-05-07 2002-11-14 Biohub Co., Ltd. A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
JP4499979B2 (ja) * 2001-05-21 2010-07-14 コンビ株式会社 病原菌感染抑制用組成物
WO2002098440A1 (en) * 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Drugs for diabetes
JP4826696B2 (ja) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 血管新生阻害剤
US7977379B2 (en) 2002-05-15 2011-07-12 Bhn Co., Ltd. Method for angiogenesis inhibition or immunostimulation
JP4681801B2 (ja) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 血管新生阻害剤およびその製造方法
JP2005089417A (ja) * 2003-09-19 2005-04-07 Noevir Co Ltd 糖尿病予防・治療用組成物
JP4587441B2 (ja) * 2004-02-12 2010-11-24 株式会社クレハ 新規な糖尿病治療剤および食品
US8034386B2 (en) 2004-09-17 2011-10-11 Ssi Co., Ltd. Extract from Agaricus blazei Murill capable of suppressing breast cancer
JP2006273835A (ja) * 2005-03-04 2006-10-12 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
US20120128856A1 (en) * 2009-07-31 2012-05-24 Ming East-West, Llc Maitake mushroom coffee
JPWO2011081024A1 (ja) * 2009-12-29 2013-05-09 株式会社富士見養蜂園 旨味食品及びその製造方法
CN106309511A (zh) * 2016-08-30 2017-01-11 青海民族大学 圆孢蘑菇抑制cdc25酶有效部位及制法和应用
CN106333969A (zh) * 2016-08-30 2017-01-18 青海民族大学 圆孢蘑菇抑制hdac1酶有效部位及制法和应用
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (ko) * 2020-12-16 2024-03-12 대한민국 잎새버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102602787B1 (ko) * 2020-12-16 2023-11-17 대한민국 꽃송이버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102584680B1 (ko) * 2020-12-17 2023-10-06 대한민국 생리활성 및 영양성분이 증가된 표고버섯차 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (de) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Energetische anregung biologischer arzneimittel
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (ja) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍機能を有する食品及びその製造法
JP3357383B2 (ja) * 1991-08-14 2002-12-16 昌宏 黒田 低分子化植物性組成物
JP2955126B2 (ja) * 1992-06-22 1999-10-04 笑代 丹羽 医薬用油性製剤、食品用油性製剤およびそれらの製造方法
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
CA2282234A1 (en) 2000-03-17
NO994463L (no) 2000-03-20
SE0100195D0 (sv) 2001-01-24
ES2155802A1 (es) 2001-05-16
ID23150A (id) 2000-03-23
GB2341800A (en) 2000-03-29
NL1013049C2 (nl) 2002-01-11
FR2788697A1 (fr) 2000-07-28
SE9903307D0 (sv) 1999-09-16
CN1255376A (zh) 2000-06-07
GB9920710D0 (en) 1999-11-03
BE1012725A5 (fr) 2001-02-06
SG76631A1 (en) 2000-11-21
AU4486299A (en) 2000-03-30
NL1019705A1 (nl) 2002-01-29
GB9921387D0 (en) 1999-11-10
NL1013049A1 (nl) 2000-03-21
JP2000159682A (ja) 2000-06-13
KR20000023206A (ko) 2000-04-25
ITTO990784A1 (it) 2001-03-14
NO994463D0 (no) 1999-09-15
IT1307267B1 (it) 2001-10-30
SE9903307L (sv) 2000-03-18
NL1019705C2 (nl) 2002-03-26
IL131722A0 (en) 2001-03-19
ITTO990784A0 (it) 1999-09-14
FR2783426A1 (fr) 2000-03-24
DK199901235A (da) 2000-03-18
DE19944695A1 (de) 2000-03-30
SE0100195L (sv) 2001-01-24
ES2155802B1 (es) 2001-12-01

Similar Documents

Publication Publication Date Title
IS5183A (is) Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
Antman et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25)
NO20004654L (no) Gastrobeskyttede omeprazolmikrogranuler, fremgangsmÕte for Õ oppnÕ slike og farmasøytiske preparater
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
NO20052410D0 (no) Vannloselige jernkarbobydratkomplekser, produksjon derav og medikamenter inneholdende disse komplekser
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
NO20033440L (no) Behandling av neurologisk dysfunksjon innbefattende fruktopyranosesulfamater og erytropoietin
IS6202A (is) Lyfjauppskriftir og aðferðir til að gefa morfín ínös
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
CY2367B1 (en) Swallow tablet comprising paracetamol.
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
TR199801871A3 (tr) Bifenilsulfonilsiyanamidler üretim yöntemi ve ilaç olarak kullanimlari.
RU2003102402A (ru) Способ формирования билатерального концепетлевого панкреатоэнтероанастомоза после медиальной резекции поджелудочной железы
IS5809A (is) Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar
MXPA02002565A (es) Procedimiento para hacer hidrolizados de proteina a partir de peptona anumal y para conservar la mucosa.
ZA200007111B (en) Methods and devices for providing prolonged drug therapy.
NL1017117A1 (nl) Werkwijze voor de versterking van de antitumoractiviteit van een amygdalinebevattend materiaal, preparaat dat versterkt amygdalinebevattend materiaal bevat, werkwijze ter beoordeling van de antitumoreffectiviteit van een behandeling van amygdalinebevattend materiaal, en werkwijze ter beoordeling van amygdalinebevattend antitumormateriaal.
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
IS5621A (is) Fiskfóður til eldis, form samsetningar, og aðferðtil gjafar
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.